Suprachoroidal Triamcinolone Acetonide for the Treatment of Refractory Macular Edema Secondary to Non-Infectious Uveitis

Introduction Suprachoroidal triamcinolone acetonide (TA) was recently FDA-approved and is emerging as a new alternative to other local therapies for macular edema (ME) associated with noninfectious uveitis (NIU). Methods This was a retrospective review of our initial experience with a cohort of patients with refractory ME secondary to NIU treated with suprachoroidal TA from November 2022 to October 2023. Data collected included demographics, ophthalmic history, as well as exam and imaging findings at baseline and follow-up visits. Results Six eyes from 5 patients with refractory ME secondary to NIU were included in the study. The cohort included 2 females (40%) and the median age was 62 years (IQR = 8). Ophthalmic diagnoses included intermediate uveitis (n = 2; 40%), birdshot chorioretinopathy (n = 1; 20%), autoimmune retinopathy (n = 1; 20%), and panuveitis (n = 1; 20%). The median logMAR visual acuity was 0.7 (Snellen 20/100) at baseline and improved to 0.3 (Snellen 20/40) during follow-up visits at 1 month and 2–3 months. The median central subfield thickness (CST) was 690 µm at baseline and improved to 367.5 µm and 309 µm at the follow-up visits at 1 month and 2–3 months, respectively. The initial improvement in logMAR visual acuity and CST was less pronounced at follow-up visits at 6–7 months and 11–12 months. Conclusions This study demonstrates the safety of suprachoroidal TA and efficacy signals including improvement in visual acuity and ME at 3 months in patients with severe, refractory ME secondary to NIU.